While HBV-specific CD8+ T cells are key effectors that mediate both hepatocellular injury and virus control (1–3), a paradigm has been emerging in the past decade, positing that multiple immune subsets participate in HBV-associated liver disease pathogenesis (9–14). The gene discussed is CD8A; the disease is liver disorder.